XML 70 R56.htm IDEA: XBRL DOCUMENT
v3.19.1

Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018
--- | --- | ---
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Deferred revenue |  | $ 63,284
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Upfront and Milestone Payments |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Deferred revenue | $ 65,072 |
ZIOPHARM Oncology, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Deferred revenue |  | 1,214
ZIOPHARM Oncology, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Average remaining performance period (in years) | 15 days |
ZIOPHARM Oncology, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Upfront and Milestone Payments |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Deferred revenue | $ 628 |
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Deferred revenue |  | 5,810
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Average remaining performance period (in years) | 5 years 2 months 12 days |
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Upfront and Milestone Payments |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Deferred revenue | $ 5,669 |
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Deferred revenue |  | 10,267
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Average remaining performance period (in years) | 5 years |
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Upfront and Milestone Payments |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Deferred revenue | $ 9,659 |
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Deferred revenue |  | 14,060
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Average remaining performance period (in years) | 5 years 8 months 12 days |
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Upfront and Milestone Payments |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Deferred revenue | $ 13,556 |
Genopaver, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Deferred revenue |  | 1,175
Genopaver, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Average remaining performance period (in years) | 5 years |
Genopaver, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Upfront and Milestone Payments |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Deferred revenue | $ 1,238 |
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Deferred revenue |  | 17,519
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Average remaining performance period (in years) | 5 years 10 months 24 days |
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Upfront and Milestone Payments |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Deferred revenue | $ 17,192 |
Persea Bio, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Deferred revenue |  | 2,697
Persea Bio, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Average remaining performance period (in years) | 5 years 9 months 18 days |
Persea Bio, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Upfront and Milestone Payments |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Deferred revenue | $ 4,070 |
Harvest start-up entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Deferred revenue |  | 7,644
Harvest start-up entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Average remaining performance period (in years) | 5 years 10 months 24 days |
Harvest start-up entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Upfront and Milestone Payments |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Deferred revenue | $ 7,260 |
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Deferred revenue |  | $ 2,898
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Average remaining performance period (in years) | 2 years |
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Upfront and Milestone Payments |  |
Contract With Customer, Asset And Liability [Line Items] |  |
Deferred revenue | $ 5,800 |

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition [Line Items] for Contract With Customer, Asset And Liability [Table] + References No definition available. + Details
Name: | xon_ContractWithCustomerAssetAndLiabilityLineItems
Namespace Prefix: | xon_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2019-01-01
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xon_UpfrontAndMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2019-04-01
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xon_ZiopharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xon_OragenicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xon_IntrexonEnergyPartnersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xon_IntrexonEnergyPartnersIILLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xon_GenopaverLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xon_FibrocellMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xon_PerseaBioLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xon_HarvestStartUpEntitiesAggregatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xon_OtherCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |